USRE37285EExpiredUtilityPatentIndex 82

Polyoxypropylene/polyoxyethylene copolmers with improved biological activity

Assignee: CYTRX CORPPriority: Mar 19, 1991Filed: Nov 19, 1999Granted: Jul 17, 2001

Est. expiryMar 19, 2011(expired)· nominal 20-yr term from priority

Inventors:EMANUELE R MARTIN HUNTER ROBERT L CULBRETH PAULA H

A61K 31/765C08G 65/2624A61K 45/06A61K 31/77C08G 65/2609A61K 47/56C08G 65/30A61P 7/02A61K 47/60C08G 65/08

PatentIndex Score

Cited by

140

References

Claims

Abstract

The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

Claims

exact text as granted — not AI-modified

We claim:

1. A method for treating sickle cell anemia comprising administering to a human with sickle cell anemia a composition comprising a polyoxyethylene/polyoxypropylene block copolymer composition, said block copolymer composition consisting essentially of block copolymers with each of the block copolymers having the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

wherein “a” is an integer such that the molecular weight represented by the polyoxypropylene portion of the respective block copolymer is between approximately 900 and 1500 daltons and “b” is an integer such that the molecular weight represented by the polyoxyethylene portion of the respective block copolymer constitutes between approximately 5% and 90 95% of the respective block copolymer and the polydispersity value of the block copolymer composition is less than approximately 1.07 and the block copolymer composition is substantially free of unsaturation as measured by nuclear magnetic resonance spectroscopy .

2. The method of claim 1 , wherein the polydispersity value of the copolymer is less than approximately 1.05.

3. The method of claim 1 , wherein the polydispersity value of the copolymer is less than approximately 1.03.

4. The method of claim 1 , wherein the copolymer is substantially free of unsaturation.

5. The method of claim 1 , wherein the respective block copolymer has a molecular weight range of between approximately 1,200 and 6,500 daltons.

6. The method of claim 5 , wherein the polyoxyethylene portion of the respective block copolymer constitutes between approximately 10% and 90% of the respective block copolymer.

7. The method of claim 1 , wherein each of the block copolymer copolymers has the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

wherein “a” is an integer such that the molecular weight represented by the polyoxypropylene portion of the respective block copolymer is approximately 1750 daltons and the total molecular weight of the respective block copolymer is approximately 8400 and the polydispersity value is less than approximately 1.07 daltons .

8. A method for improving blood flow comprising administering to a human or animal a composition comprising a polyoxyethylene/polyoxypropylene block copolymer composition, said block copolymer composition consisting essentially of block copolymers with each of the block copolymers having the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

9. The method of claim 8 , wherein the polydispersity value of the copolymer is less than approximately 1.05.

10. The method of claim 8 , wherein the polydispersity value of the copolymer is less than approximately 1.03.

11. The method of claim 8 , wherein the copolymer is substantially free of unsaturation.

12. The method of claim 8 wherein the respective block copolymer has a molecular weight range of between approximately 1,200 and 6,500 daltons.

13. The method of claim 12 , wherein the polyoxyethylene portion of the respective block copolymer constitutes between approximately 10% and 90% of the respective block copolymer.

14. The method of claim 1 8 , wherein each of the block copolymercopolymers has the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

15. A method for treating ischemia comprising administering to a human or animal with ischemia a composition comprising a polyoxyethylene/polyoxypropylene block copolymer composition, said block copolymer composition consisting essentially of block copolymers with each of the block copolymers having the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

16. The method of claim 15 , wherein the polydispersity value of the copolymer is less than approximately 1.05.

17. The method of claim 15 , wherein the polydispersity value of the copolymer is less than approximately 1.03.

18. The method of claim 15 , wherein the copolymer is substantially free of unsaturation.

19. The method of claim 15 , wherein the respective block copolymer has a molecular weight range of between approximately 1,200 and 6,500 daltons.

20. The method of claim 19 , wherein the polyoxyethylene portion of the respective block copolymer constitutes between approximately 10% and 90% of the respective block copolymer.

21. The method of claim 15 , wherein each of the block copolymer copolymers has the following general formula:

HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.